Clinical Trial

To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-13.
Trial Details
NCT Number NCT07479043
Lead Sponsor Breathe Biologics, Inc.
Conditions Acute Respiratory Distress Syndrome
Enrollment 128 participants
Start Date 2026-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-19